Vor Biopharma (VOR) Consolidated Net Income (2020 - 2026)
Vor Biopharma (VOR) reported Consolidated Net Income of -$31.2 million for Q1 2026, up 3.88% year-over-year from -$30.1 million in Q1 2025, and up 5.85% on a QoQ basis from -$33.2 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Consolidated Net Income data on file, last reported at -$31.2 million in Q1 2026.
- Quarterly Consolidated Net Income rose 3.88% year-over-year to -$31.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$364.5 million (down 207.36% YoY) and the FY2025 annual result came in at -$365.8 million, down 212.86% from the prior year.
- Consolidated Net Income climbed to -$31.2 million in Q1 2026 per VOR's latest filing, from -$33.2 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$21.7 million in Q2 2022 and bottomed at -$273.7 million in Q2 2025.
- The 5-year median for Consolidated Net Income is -$28.4 million (2023), against an average of -$42.6 million.
- The widest annual swing landed in 2024, when Consolidated Net Income climbed 16.97%; it then tumbled 883.32% in 2025.
- Tracing VOR's Consolidated Net Income over 5 years: stood at -$23.9 million in 2022, then dropped by 9.83% to -$26.3 million in 2023, then fell by 16.95% to -$30.7 million in 2024, then dropped by 7.99% to -$33.2 million in 2025, then rose by 5.85% to -$31.2 million in 2026.
- Per Business Quant, the three latest VOR Consolidated Net Income figures stand at -$31.2 million (Q1 2026), -$33.2 million (Q4 2025), and -$26.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -31.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.23 Mn |
| Dec 31, 2025 | -33.17 Mn |
| Sep 30, 2025 | -26.38 Mn |
| Jun 30, 2025 | -273.75 Mn |
| Mar 31, 2025 | -32.49 Mn |
| Dec 31, 2024 | -30.71 Mn |
| Sep 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.84 Mn |
| Mar 31, 2024 | -30.80 Mn |
| Dec 31, 2023 | -26.26 Mn |
| Sep 30, 2023 | -33.19 Mn |
| Jun 30, 2023 | -29.98 Mn |
| Mar 31, 2023 | -28.43 Mn |
| Dec 31, 2022 | -23.91 Mn |
| Sep 30, 2022 | -23.79 Mn |
| Jun 30, 2022 | -21.66 Mn |
| Mar 31, 2022 | -22.74 Mn |
| Dec 31, 2021 | -18.25 Mn |
| Sep 30, 2021 | -18.55 Mn |
| Jun 30, 2021 | -18.37 Mn |
| Mar 31, 2021 | -13.72 Mn |
| Dec 31, 2020 | -15.66 Mn |
| Sep 30, 2020 | -11.79 Mn |
| Jun 30, 2020 | -8.04 Mn |
| Mar 31, 2020 | -7.85 Mn |